Get the Stockscreener App
18.07
4.56%
-0.8139
Spyre Therapeutics Inc stock is traded at $18.07, with a volume of 50,668.
It is down -4.56% in the last 24 hours and down -20.55% over the past month.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
See More
Previous Close:
$18.88
Open:
$18.74
24h Volume:
50,668
Relative Volume:
0.09
Market Cap:
$1.12B
Revenue:
$1.23M
Net Income/Loss:
$-214.90M
P/E Ratio:
-4.3826
EPS:
-4.1222
Net Cash Flow:
$-151.25M
1W Performance:
-12.10%
1M Performance:
-20.55%
6M Performance:
-38.62%
1Y Performance:
-59.51%
1-Day Range:
$18.01
$19.00
1-Week Range:
$17.25
$21.03
52-Week Range:
$17.25
$47.97
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
(617) 651-5940
Address
221 CRESCENT STREET, WALTHAM
Compare SYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
18.06 | 1.12B | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
498.17 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
678.01 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.05 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.79 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.13 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-24 | Initiated | Wedbush | Outperform |
| Jul-16-24 | Initiated | Evercore ISI | Outperform |
| May-02-24 | Initiated | Robert W. Baird | Outperform |
| Mar-01-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
Spyre Therapeutics Announces Grants of Inducement Awards - cnhinews.com
Spyre Therapeutics Inc (SYRE) Announces Stock Option Grants to Non-Executive Employees - GuruFocus.com
132,200 New Stock Options: Inside Spyre Therapeutics' Latest Employee Compensation Package - StockTitan
Rhumbline Advisers Boosts Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company Status - MSN
Spyre Therapeutics Inc (SYRE) deserves closer scrutiny - US Post News
Spyre Therapeutics: Targeting The Future Of IBD Treatment - Seeking Alpha
Spyre Therapeutics (NASDAQ:SYRE) Trading 6.6% Higher After Strong Earnings - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Posts Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Buy Rating for Spyre Therapeutics Driven by Promising Drug Development and Strong Financial Position - TipRanks
Spyre Therapeutics: Q4 Earnings Snapshot - The Pioneer
Decoding Spyre Therapeutics Inc (SYRE): A Strategic SWOT Insight - GuruFocus.com
Buy Rating for Spyre Therapeutics: Promising Pipeline and Strategic Advancements Drive Growth Potential - TipRanks
Spyre Therapeutics Reports Strong Progress and Financial Stability - TipRanks
Spyre Therapeutics reports Q4 EPS (81c), consensus (94c) - TipRanks
Spyre Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - PR Newswire
Spyre Therapeutics (SYRE) Projected to Post Earnings on Thursday - Defense World
Recent Insider Activity Could Benefit Spyre Therapeutics Inc (SYRE) - Knox Daily
SYRE Stock Touches 52-Week Low at $20.24 Amid Market Challenges - Investing.com Australia
Spyre Therapeutics (NASDAQ:SYRE) Hits New 1-Year LowTime to Sell? - MarketBeat
Spyre Therapeutics to Participate in Upcoming March Investor Conferences - PR Newswire
Spyre Therapeutics (NASDAQ:SYRE) Upgraded at The Goldman Sachs Group - Defense World
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Can This Novel Dual-Action IBD Treatment Transform Patient Care? New Data Reveals Promising Results - StockTitan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Analysts - Defense World
1,955 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call - MSN
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect? - MSN
InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call By Investing.com - Investing.com
Spyre (SYRE) Unveils Strategic Talent Retention Plan: 35K Options with 10-Year Window - StockTitan
China Universal Asset Management Co. Ltd. Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - cnhinews.com
A company insider recently sold 6,700 shares of Spyre Therapeutics Inc [SYRE]. Should You also Consider to Sale? - Knox Daily
Financial Analysis: Spyre Therapeutics Inc (SYRE)’s Ratios Unveil Key Insights - The Dwinnex
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - PR Newswire
Spyre Therapeutics Inc (SYRE) stock analysis: A comprehensive overview - US Post News
Oruka Therapeutics initiated with an Outperform at Wolfe Research - MSN
JPMorgan Chase & Co. Has $867,000 Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Assenagon Asset Management S.A. Has $527,000 Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Assenagon Asset Management S.A. Cuts Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Target Price at $54.83 - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 9.4%Time to Buy? - MarketBeat
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Spyre Therapeutics Inc Stock (SYRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Albers Jeffrey W. | Director |
Oct 25 '24 |
Sale |
36.43 |
300 |
10,929 |
34,060 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):